荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02509 荃信生物-B

已收盘 07-27 16:08:02

16.200

+0.000

0.00%

最高16.430	最低16.070	成交量2.74万
今开16.070	昨收16.200	日振幅2.22%
总市值36.13亿	流通市值36.13亿	总股本2.23亿
成交额44.44万	换手率0.01%	流通股本2.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":16.2,"timestamp":1785139682311,"preClose":16.2,"halted":0,"volume":27400,"delay":0,"changeRate":0,"floatShares":223000000,"shares":223000000,"eps":1.41,"marketStatus":"已收盘","change":0,"latestTime":"07-27 16:08:02","open":16.07,"high":16.43,"low":16.07,"amount":444404,"amplitude":0.022222,"askPrice":16.39,"askSize":200,"bidPrice":16.2,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.564286,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785202200000},"marketStatusCode":5,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":16.2,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":0.253704,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509/wiki","defaultTab":"wiki","newsList":[{"id":"1186215746","title":"荃信生物-B回购1000股股份，耗资约1.60万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186215746","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186215746?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:32","pubTimestamp":1784280730,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年7月17日发布公告，披露公司于香港联交所场内回购1000股普通股H股。该批股份占回购前已发行股本的约0.00045%，每股回购价为每股15.99港元，涉资总额约1.60万港元。本次回购股份将被持作库藏股。公告显示，经本次变动后，公司已发行股份总数仍为227,071,600股，其中在外流通股数为223,369,200股，库藏股数则增至3,702,400股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B回购1000股股份，耗资约1.60万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652401327","title":"荃信生物-B(02509)7月17日耗资约1.6万港元回购1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652401327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652401327?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:30","pubTimestamp":1784280616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)公布，2026年7月17日耗资约1.6万港元回购1000股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180232421","title":"荃信生物-B回购3,000股，耗资约4.52万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180232421","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180232421?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:26","pubTimestamp":1783592809,"startTime":"0","endTime":"0","summary":"江苏荃信生物医药股份有限公司于2026年7月9日发布公告，称公司当日通过香港联交所场内回购3,000股H股，占回购前已发行股本的约0.001343%。本次回购价格为每股15.08港元，总耗资约4.52万港元。公告显示，回购完成后，公司已发行股本总数仍为227,071,600股，其中不含库存股份的已发行股本由223,373,200股下降至223,370,200股，库存股份数量由3,698,400股增至3,701,400股。本次回购后，公司在新股发行及库存股份出售或转让方面将适用的暂止期截至2026年8月8日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B回购3,000股，耗资约4.52万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650237739","title":"荃信生物-B(02509)7月9日斥资约4.52万港元回购3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650237739","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650237739?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:23","pubTimestamp":1783592617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年7月9日该公司斥资约4.52万港元回购3000股，回购价格为每股15.08港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174667974","title":"荃信生物-B：7月8日回购600股，耗资约9,420港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174667974","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174667974?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:37","pubTimestamp":1783507076,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年7月8日根据股份回购授权，在香港联合交易所场内回购600股普通股，约占当日公司现有已发行股本的0.00027%，每股回购价格为15.70港元，合计耗资9,420港元。公告日期为2026年7月8日。本次回购完成后，截至2026年7月8日，荃信生物-B的已发行股本总数仍为227,071,600股，其中流通股数量减少至223,373,200股，库藏股数量增至3,698,400股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B：7月8日回购600股，耗资约9,420港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174266156","title":"荃信生物-B：7月7日回购8000股，耗资约12.56万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174266156","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174266156?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:02","pubTimestamp":1783422137,"startTime":"0","endTime":"0","summary":"2026年7月7日，江苏荃信生物医药股份有限公司发布翌日报表公告，披露于当日通过香港联交所场内回购普通股（H股）8,000股，占回购前已发行股本约0.0036%。每股回购价为15.70港元，涉资约12.56万港元。截至本次回购后，公司累计根据该授权购回股份数量为989,600股，占授权获通过当日已发行股本总数的0.4411%。公司方面确认已遵守香港联合交易所有限公司证券上市规则的相关规定。本次公告由董事会秘书和联席公司秘书胡衍保签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荃信生物-B：7月7日回购8000股，耗资约12.56万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981486","title":"荃信生物-B(02509.HK)7月7日耗资12.56万港元回购8000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981486","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649981486?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:55","pubTimestamp":1783421743,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113868491","title":"荃信生物-B更新6月股份变动月报表，股本总量保持227,071,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113868491","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113868491?lang=zh_cn&edition=full","pubTime":"2026-07-07 09:11","pubTimestamp":1783386713,"startTime":"0","endTime":"0","summary":"2026年7月7日，江苏荃信生物医药股份有限公司公布2026年6月股份变动月报表，披露了截至2026年6月30日的股本结构及相关变动情况。根据公告显示，荃信生物-B的法定及注册股本本月维持不变，仍为人民币227,071,600元。期末已发行股份为223,381,800股，较上月底的224,363,400股减少981,600股；同时，库藏股份从2,708,200股增加至3,689,800股，总股本保持在227,071,600股。该等回购股份暂未注销，全部被作为库藏股份持有。公告由董事会秘书和联席公司秘书胡衍保签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617234","title":"港股异动 | 荃信生物-B(02509)涨超8% CLD-423注射液获批临床 公司创新性管线出海授权陆续达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617234","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649617234?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304433,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超8%，截至发稿，涨8.12%，报16.65港元，成交额144.38万港元。消息面上，近日，CDE官网显示，荃信生物申报的CLD-423注射液获批临床，拟开发治疗克罗恩病。公开资料显示，QX030N/CLD-423是一款双特异性抗体，靶向经临床验证的IL-23p19和TL1A通路，拟开发用于治疗炎症性肠病及其他免疫性和炎症性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","02509","BK1161","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649172316","title":"港股异动 | 荃信生物-B(02509.HK)涨超8% CLD-423注射液获批临床 公司创新性管线出海授权陆续达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2649172316","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649172316?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304433,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648574371","title":"港股异动 | 荃信生物-B(02509.HK)最高涨超7% 收购赛孚士强化内部协同效应 加速旗下QX002N等核心产品审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2648574371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648574371?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:09","pubTimestamp":1782972569,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160149677","title":"荃信生物-B：6月30日回购3,200股，耗资约4.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160149677","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160149677?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:45","pubTimestamp":1782819942,"startTime":"0","endTime":"0","summary":"2026年6月30日，荃信生物-B发布公告，披露公司于当日在香港联交所场内回购3,200股H股，占回购前公司已发行股本223,385,000股的约0.0014%。本次回购价格介乎每股14.23港元至14.50港元，累计耗资约45,812.16港元。回购后，公司已发行股本维持在227,071,600股，其中库存股增至3,689,800股。公告显示，本次回购依据2026年5月29日通过的购回授权进行。根据授权，公司可回购的股份总数为22,436,340股，至今已回购股份的累计数量为981,600股，占前述授权获批时已发行股本约0.4375%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B：6月30日回购3,200股，耗资约4.58万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558712","title":"荃信生物-B(02509)6月30日耗资约4.58万港元回购3200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558712","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647558712?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:42","pubTimestamp":1782819739,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)公布，2026年6月30日耗资约4.58万港元回购3200股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647808325","title":"港股异动 | 荃信生物-B(02509)涨超8% 拟收购赛孚士剩余股权 促进两款核心管线产品新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2647808325","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647808325?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:55","pubTimestamp":1782712532,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超8%，截至发稿，涨8.18%，报14.81港元，成交额297.66万港元。消息面上，荃信生物-B发布公告，于2026年6月26日，赛孚聚力与泰州华诚订立股权转让协议，赛孚聚力有条件同意收购，而泰州华诚有条件同意出售目标股权，代价为人民币8602万元。收购事项完成后，本公司将通过赛孚聚力间接拥有赛孚士100%的股权。收购事项旨在促进本集团核心管线产品鲁塞奇塔单抗及奥托奇拜单抗的新药上市申请顺利提交和审批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","IPOS","02509","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647332580","title":"港股异动 | 荃信生物-B(02509.HK)涨超8% 拟收购赛孚士剩余股权 促进两款核心管线产品新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2647332580","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647332580?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:55","pubTimestamp":1782712532,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646136504","title":"荃信生物-B(02509.HK)以8602万元收购赛孚士34%股权 实现全资控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646136504","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646136504?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:47","pubTimestamp":1782485224,"startTime":"0","endTime":"0","summary":"格隆汇6月26日丨荃信生物-B(02509.HK)宣布，于2026年6月26日，赛孚聚力(公司全资附属公司)与泰州华诚订立股权转让协议，据此，赛孚聚力有条件同意收购，而泰州华诚有条件同意出售目标股权(即赛孚士约34.0001%的股权)，代价为人民币8602万元。股权转让将于在相关当局完成股权变更登记之日(赛孚聚力须在悉数支付代价及签署股权转让协议后30个营业日内促成)落实。\r\n\r\n　　于本公告日期，公司通过赛孚聚力间接拥有赛孚士约65.9999%的股权。收购事项完成后，公司将通过赛孚聚力间接拥有赛孚士100%的股权。赛孚士将成为公司的全资附属公司，其财务业绩将继续综合入账至集团综合财务报表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260626/32291932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117769030","title":"荃信生物完成对赛孚士34%股权收购　交易额86.02百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117769030","media":"公告速递","labels":["corporation","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117769030?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:16","pubTimestamp":1782483372,"startTime":"0","endTime":"0","summary":"6月26日，荃信生物-B公告，全资子公司赛孚聚力与泰州华诚签署股权转让协议，以86.02百万元现金收购其持有的赛孚士34.0001%股权。交易落地后，荃信生物将通过赛孚聚力间接持有赛孚士100%股权，赛孚士变更为公司全资附属公司。由于适用百分比率介于5%至25%之间，此次收购构成《上市规则》第14章项下的须予披露交易；同时，泰州华诚为赛孚士主要股东，交易亦构成关连交易，但根据第14A.101条，仅需履行公告及申报义务，无需刊发通函及取得股东批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173231099","title":"荃信生物-B：6月26日回购4,800股，耗资约6.56万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173231099","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173231099?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:52","pubTimestamp":1782471169,"startTime":"0","endTime":"0","summary":"江蘇荃信生物醫藥股份有限公司2026年6月26日发布翌日披露报表，显示公司当日于香港联交所场内回购H股股份4,800股，占当日该公司已发行股份总数的约0.0021%。回购价格区间为每股13.58港元至13.69港元，合计耗资65,604港元。本次回购后，公司已发行股份总数为227,071,600股，其中223,385,000股为已发行股份，3,686,600股为库存股份。根据公告，荃信生物-B已于2026年5月29日获股东大会通过购回授权，允许购回的股份总数为22,436,340股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B：6月26日回购4,800股，耗资约6.56万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646359222","title":"荃信生物-B(02509)6月26日斥资6.56万港元回购4800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646359222","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646359222?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:50","pubTimestamp":1782471026,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2026年6月26日，该公司斥资6.56万港元回购4800股股份，每股回购价13.58-13.69港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106940532","title":"荃信生物-B于6月22日回购1.26万股，耗资约17.48万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106940532","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106940532?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:52","pubTimestamp":1782125576,"startTime":"0","endTime":"0","summary":"荃信生物-B于2026年6月22日公告，宣布在香港联交所场内回购12,600股，占公司已发行股本约0.0056%。本次回购每股价格介乎港币13.4元至13.99元，总计约17.48万港元。\n公司回购完成后，已发行股本数量变动至223,389,800股，库藏股增至3,681,800股。回购授权于2026年5月29日获得通过，公司可根据该授权回购剩余股份数为22,436,340股。公司确认本次回购活动已遵守香港联交所主板上市规则及相关法律程序。\n公告由董事会秘书和联席公司秘书胡衍保签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荃信生物-B于6月22日回购1.26万股，耗资约17.48万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":0.1748},{"period":"3month","weight":-0.1005},{"period":"6month","weight":-0.2582},{"period":"1year","weight":-0.1243},{"period":"ytd","weight":-0.1374}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事自身免疫及过敏性疾病的生物疗法研发、制造及商业化的中国公司。该公司专注于皮肤、风湿、呼吸道及消化道疾病。该公司的产品主要包括赛乐信、奥托奇拜单抗，以及鲁塞奇塔单抗等。该公司在国内和国外市场开展业务。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}